Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. raised its stake in shares of Royalty Pharma plc (NASDAQ:RPRX) by 12.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 36,643 shares of the biopharmaceutical company’s stock after purchasing an additional 4,007 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Royalty Pharma were worth $1,029,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Allworth Financial LP increased its position in Royalty Pharma by 89.8% during the third quarter. Allworth Financial LP now owns 953 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 451 shares during the last quarter. Toroso Investments LLC increased its position in shares of Royalty Pharma by 0.9% in the third quarter. Toroso Investments LLC now owns 57,102 shares of the biopharmaceutical company’s stock worth $1,550,000 after acquiring an additional 504 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Royalty Pharma by 112.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,005 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 531 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Royalty Pharma by 10.8% in the third quarter. PNC Financial Services Group Inc. now owns 5,509 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 536 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. increased its position in shares of Royalty Pharma by 8.0% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 8,210 shares of the biopharmaceutical company’s stock worth $223,000 after acquiring an additional 607 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Price Performance

RPRX opened at $27.98 on Thursday. The company has a fifty day simple moving average of $29.69 and a 200 day simple moving average of $28.54. The firm has a market cap of $16.72 billion, a price-to-earnings ratio of 14.80 and a beta of 0.45. Royalty Pharma plc has a twelve month low of $25.92 and a twelve month high of $35.95. The company has a current ratio of 7.90, a quick ratio of 7.90 and a debt-to-equity ratio of 0.61.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.12. Royalty Pharma had a net margin of 48.22% and a return on equity of 26.93%. The business had revenue of $736.00 million during the quarter, compared to analyst estimates of $702.90 million. Equities research analysts expect that Royalty Pharma plc will post 3.95 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 17th will be paid a dividend of $0.21 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $0.84 dividend on an annualized basis and a yield of 3.00%. Royalty Pharma’s dividend payout ratio (DPR) is 44.44%.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, April 11th. JPMorgan Chase & Co. dropped their price objective on shares of Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating for the company in a research report on Tuesday, February 20th. Bank of America dropped their price objective on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a research report on Friday, April 12th. Finally, The Goldman Sachs Group lowered their price target on shares of Royalty Pharma from $56.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, February 20th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Royalty Pharma has a consensus rating of “Buy” and a consensus target price of $46.75.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.